Your browser doesn't support javascript.
loading
Advax augments B and T cell responses upon influenza vaccination via the respiratory tract and enables complete protection of mice against lethal influenza virus challenge.
Tomar, Jasmine; Patil, Harshad P; Bracho, Gustavo; Tonnis, Wouter F; Frijlink, Henderik W; Petrovsky, Nikolai; Vanbever, Rita; Huckriede, Anke; Hinrichs, Wouter L J.
Afiliación
  • Tomar J; Department of Pharmaceutical Technology and Biopharmacy, University of Groningen, Groningen, The Netherlands.
  • Patil HP; Advanced Drug Delivery & Biomaterials, Louvain Drug Research Institute (LDRI), Université catholique de Louvain, Brussels 1200, Belgium.
  • Bracho G; Vaxine Pty Ltd., Flinders Medical Centre, Bedford Park, Adelaide 5042, Australia.
  • Tonnis WF; Department of Pharmaceutical Technology and Biopharmacy, University of Groningen, Groningen, The Netherlands.
  • Frijlink HW; Department of Pharmaceutical Technology and Biopharmacy, University of Groningen, Groningen, The Netherlands.
  • Petrovsky N; Vaxine Pty Ltd., Flinders Medical Centre, Bedford Park, Adelaide 5042, Australia; Department of Diabetes and Endocrinology, Flinders University, Adelaide 5042, Australia.
  • Vanbever R; Advanced Drug Delivery & Biomaterials, Louvain Drug Research Institute (LDRI), Université catholique de Louvain, Brussels 1200, Belgium.
  • Huckriede A; Department of Medical Microbiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
  • Hinrichs WLJ; Department of Pharmaceutical Technology and Biopharmacy, University of Groningen, Groningen, The Netherlands. Electronic address: w.l.j.hinrichs@rug.nl.
J Control Release ; 288: 199-211, 2018 10 28.
Article en En | MEDLINE | ID: mdl-30218687
ABSTRACT
Administration of influenza vaccines via the respiratory tract has potential benefits over conventional parenteral administration, inducing immunity directly at the site of influenza exposure as well as being needle free. In this study, we investigated the suitability of Advax™, a stable particulate polymorph of inulin, also referred to as delta inulin, as a mucosal adjuvant for whole inactivated influenza vaccine (WIV) administered either as a liquid or dry powder formulation. Spray freeze-drying produced Advax-adjuvanted WIV powder particles in a size range (1-5 µm) suitable for inhalation. The physical and biological characteristics of both WIV and Advax remained unaltered both by admixing WIV with Advax and by spray freeze drying. Upon intranasal or pulmonary immunization, both liquid and dry powder formulations containing Advax induced significantly higher systemic, mucosal and cellular immune responses than non-adjuvanted WIV formulations. Furthermore, pulmonary immunization with Advax-adjuvanted WIV led to robust memory B cell responses along with an increase of lung localization factors i.e. CXCR3, CD69, and CD103. A less pronounced but still positive effect of Advax was seen on memory T cell responses. In contrast to animals immunized with WIV alone, all animals pulmonary immunized with a single dose of Advax-adjuvanted WIV were fully protected with no visible clinical symptoms against a lethal dose of influenza virus. These data confirm that Advax is a potent mucosal adjuvant that boosts vaccine-induced humoral and cellular immune responses both in the lung and systemically with major positive effects on B-cell memory and complete protection against live virus. Hence, respiratory tract immunization, particularly via the lungs, with Advax-adjuvanted WIV formulation as a liquid or dry powder is a promising alternative to parenteral influenza vaccination.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vacunas contra la Influenza / Vacunas de Productos Inactivados / Adyuvantes Inmunológicos / Subtipo H1N1 del Virus de la Influenza A / Inulina Límite: Animals Idioma: En Revista: J Control Release Asunto de la revista: FARMACOLOGIA Año: 2018 Tipo del documento: Article País de afiliación: Países Bajos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Vacunas contra la Influenza / Vacunas de Productos Inactivados / Adyuvantes Inmunológicos / Subtipo H1N1 del Virus de la Influenza A / Inulina Límite: Animals Idioma: En Revista: J Control Release Asunto de la revista: FARMACOLOGIA Año: 2018 Tipo del documento: Article País de afiliación: Países Bajos
...